Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March). This quarter, 6 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from China, two from the EU, and one from Australia:
Vilobelimab (Gohibic)
Garadacimab (Andembry)
Finotonlimab (新替妥)
Siltartoxatug (Sintetol)
Sipavibart (Kavigale)
Teprotumumab N01 (Sycume)
Q1 2025 saw several large collaborations and acquisitions of up to USD$3.1 billion in value. The majority of collaborative efforts focused on developing novel platforms such as bispecific antibody and ADC engineering.
Gain exclusive insights into current trends such as:
6 novel antibody drugs approved for the first time in Q1
Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$3.1B
Novel platforms such as bispecific antibody and ADC engineering
Recent research into obesity and COVID-19 treatments
A list of antibody drugs in regulatory review to keep an eye out for in Q2 2025
Resistance to treatment continues to limit the long-term success of many therapies. In oncology, cancers may evade antibody-based treatments through mechanisms such as antigen loss, impaired intracellular trafficking, or suppression of immune responses. To address these challenges, researchers are d
Antibody-drug conjugates (ADCs) couple the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. Recent advances have been reported in both hematologic and solid tumors, with next-generation ADCs overcoming limitations of traditional therapies through improved t
Non–small cell lung cancer(NSCLC) remains the leading cause of cancer-related mortality worldwide. Since 2011, the U.S. Food and Drug Administration has approved over 30 new therapies for advanced NSCLC, primarily tyrosine kinase inhibitors and immune checkpoint inhibitors. Biologic age
ScientistとScience Exchangeとのご利用可能です。
